Aura Biosciences, Inc. Payments of Stock Issuance Costs
Aura Biosciences, Inc. (AURA) reported Payments of Stock Issuance Costs of $1.42 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2022-11-10
- Aura Biosciences, Inc. payments of stock issuance costs for the quarter ending 2021-09-30 was $1.14M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month |
|---|---|---|---|
| 2021-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.42M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $280.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |